AKT1 and colorectal carcinoma: These findings suggest that BEZ235 treatment not only inhibits AKT/mTOR signaling, but also attenuates DNA-DSB repair, thus contributing to increased radiosensitivity in wild and mutant p53 CRC cell lines.